Ilya Budik runs a company most patients will never notice working, which is the whole point. As CEO of CardioRenal Systems, based in Milford, Massachusetts, he leads the team behind the RenalPro System - the same core technology sold internationally as RenalGuard. It is designed to do something quiet and consequential: protect the kidneys during the high-stress hours of cardiac surgery, heart catheterization, and intensive care, when the risk of acute kidney injury climbs and often goes unaddressed.
The immediate work is a milestone Budik has been building toward for years. In 2026 the company secured an FDA Investigational Device Exemption, the regulatory green light to begin enrolling patients in a U.S. pivotal trial of RenalPro for cardiac surgery-associated acute kidney injury. Paired with that clearance came a strategic investment from a hospital system, St. Elizabeth Healthcare, and the Angel Physicians Fund - the sort of backing that signals clinicians want the device in their own operating rooms, not just on a conference slide.
The premise is deceptively simple. Cardiac surgery saves lives, but it also stresses the kidneys, and a meaningful share of patients leave the operating room with damage that lengthens their stay, raises the cost of care, and chips away at their recovery. CardioRenal's answer is a fluid-balance system that manages hydration in real time to help preserve kidney function. Budik describes it as simple and elegant technology - and the restraint is deliberate. Devices that clinicians actually adopt tend to be the ones that fit cleanly into an existing workflow rather than reinventing it.
Proof before promotion
Budik tends to let the clinical data carry the argument. The reference point he returns to is the KIDNEY Study, a 220-patient randomized, controlled trial that reported a 52% reduction in acute kidney injury with RenalGuard Therapy compared with the standard of care. That number is the spine of the company's pitch, the evidence that turns an idea about kidney protection into something a cardiac surgery program can weigh seriously.
The regulatory record has followed a steady arc. In January 2023, RenalGuard Therapy received FDA Breakthrough Device Designation for prevention of cardiac surgery-associated acute kidney injury, a status the agency reserves for technologies that could offer a meaningful advantage over existing options. Abroad, the device carries CE Mark approval for fluid balance management and is supported by multiple randomized controlled trials. Inside the United States it remains investigational, which is exactly what the new pivotal trial is meant to resolve.
An unusual toolkit
Budik pairs two degrees that rarely share a resume: finance and biochemistry, both from Miami University in Ohio. He later completed a healthcare entrepreneurship executive course through the Lahav program at Tel Aviv University. The combination shows up in how he frames the business - the science of the device on one side, the economics of hospital adoption on the other. In medtech, where a strong clinical result still has to survive a budget meeting, that dual fluency is less a novelty than a requirement.
His path into kidneys ran through the brain. Before CardioRenal, Budik was CEO of NeuroQuest, a company developing diagnostic tests for Alzheimer's and ALS, and earlier handled business development at MND Diagnostic and a global finance role at Ethicon Endo-Surgery. He has also worked as a managing partner at Imagine Bio, an innovation strategy consultancy. The through-line across those roles is consistent: build tools that change what a clinician does next, whether that is a diagnosis or an intervention.
Two names, two markets
One quirk of the business is that the same technology answers to two names. Outside the United States it is RenalGuard; inside it, RenalPro. That is not branding for its own sake but a reflection of how differently the two regulatory worlds treat a medical device - CE Mark approval in Europe on one track, the FDA's investigational-then-pivotal pathway on the other. Managing a single product across that divide is a large part of the daily job, and it is where Budik's finance instincts and his patience with clinical timelines have to coexist.
He is not a loud executive. His public quotes lean on the team and the patients rather than himself, and he shows up as faculty at cardiovascular meetings like the ICI conference rather than on the pundit circuit. The style fits the product: a device that succeeds by being reliable and nearly invisible in the room, rather than by drawing attention to itself.
What comes next
The U.S. pivotal trial is the fulcrum. If RenalPro reproduces its international results in an American study, CardioRenal moves from a company with a promising device and a breakthrough designation to one with a clear path to FDA approval and broad hospital adoption. The stated goal has stayed constant through every milestone: make kidney protection a standard part of high-risk hospitalizations, cutting the incidence and cost of acute kidney injury while protecting patients' quality of life.
For now, Budik is doing what he has done at each step - gathering the evidence, lining up the clinical and financial partners, and letting the data set the pace. It is unglamorous work aimed at an unglamorous problem. The measure of success will be a number in a trial readout, and whether, a few years from now, kidney protection during cardiac surgery has quietly become something surgeons simply expect.